This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabbah, E. Articles by Knip, M. Search for Related Content PubMed PubMed Citation Articles by Sabbah, E. Articles by Knip, M.

Diabetes-Associated Autoantibodies in Relation to Clinical Characteristics and Natural Course in Children with Newly Diagnosed Type 1 Diabetes¹

Department of Pediatrics (E.S., K.S., P.K., R.V., P.V., J.K., M.K.), University of Oulu FIN-90220, Oulu; the Children’s Hospital (H.K.Å.), University of Helsinki, FIN-00290 Helsinki; Medical School, University of Tampere and Department of Pediatrics, Tampere University Hospital (M.K.), FIN-33101 Tampere, Finland

Address all correspondence and requests for reprints to: Dr. M. Knip, Medical School, University of Tampere, P.O. Box 607, FIN-33101 Tampere, Finland. E-mail: llmikn{at}uta.fi

We analyzed 747 children, younger than 15 yr of age, with newly diagnosed diabetes, for antibodies to glutamic acid decarboxylase (GADA), the IA-2 protein (IA-2A), insulin (IAA), and islet cells, to evaluate the influence of positivity for GADA, IA-2A, IAA, or multiple (3) autoantibodies at diagnosis, on the clinical presentation and natural course of the disease over the first 2 yr and to characterize autoantibody-negative patients. At diagnosis, 73.2% of the children tested positive for GADA, 85.7% for IA-2A, 54.2% for IAA, and 72.6% for multiple autoantibodies. Only 17 subjects (2.3%) had no detectable autoantibodies. The patients testing positive for multiple autoantibodies were younger than the remaining children (P < 0.001). A similar age difference was seen when comparing IAA-positive and -negative patients (P < 0.001). There was no significant difference between the GADA-positive and -negative subjects in the degree of metabolic decompensation at diagnosis, whereas those testing positive for IA-2A had reduced serum C-peptide concentrations (P = 0.003), and those positive for IAA had lower glycated hemoglobin values. The patients with no detectable autoantibodies had higher serum C-peptide levels (P = 0.007) at diagnosis than did the other subjects. The children initially positive for IA-2A had decreased serum C-peptide concentrations at 24 months (P = 0.045), and their daily insulin dose was higher at 18 (P = 0.005) and 24 months (P < 0.001). The patients who tested positive for multiple autoantibodies at diagnosis had decreased serum C-peptide levels (P < 0.001) and higher insulin doses (P = 0.005) at 12, 18, and 24 months. A lower proportion of them were also in clinical remission at 12 and 18 months (P = 0.01). Autoantibody-negative subjects needed less exogenous insulin at 6 and 18 (P = 0.01) and at 24 months (P < 0.001) than the other subjects, and a higher proportion of them were in clinical remission at 18 months (P < 0.001). We conclude that positivity for multiple diabetes-related autoantibodies is associated with accelerated ß-cell destruction and an increased requirement for exogenous insulin over the second year of clinical disease, indicating that multiple autoantibodies reflect an aggressive progression to total ß-cell destruction. Patients testing negative for diabetes-associated autoantibodies at diagnosis seem to have a milder degree of ß-cell destruction, but their metabolic decompensation is similar to that seen in other affected children, suggesting that they do represent classical type 1 diabetes.

This article has been cited by other articles:

				C. Pfleger, H. B. Mortensen, L. Hansen, C. Herder, B. O. Roep, H. Hoey, H.-J. Aanstoot, M. Kocova, N. C. Schloot, and on behalf of the Hvidore Study Group on Childhood Association of IL-1ra and Adiponectin With C-Peptide and Remission in Patients With Type 1 Diabetes Diabetes, April 1, 2008; 57(4): 929 - 937. [Abstract] [Full Text] [PDF]

				S. Porksen, L. B. Nielsen, A. Kaas, M. Kocova, F. Chiarelli, C. Orskov, J. J. Holst, K. B. Ploug, P. Hougaard, L. Hansen, et al. Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2910 - 2916. [Abstract] [Full Text] [PDF]

				N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]

				E. Ortqvist, E. Bjork, M. Wallensteen, J. Ludvigsson, J. Aman, C. Johansson, G. Forsander, F. Lindgren, L. Berglund, M. Bengtsson, et al. Temporary Preservation of {beta}-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes Diabetes Care, September 1, 2004; 27(9): 2191 - 2197. [Abstract] [Full Text] [PDF]

				C. Steele, W. A. Hagopian, S. Gitelman, U. Masharani, M. Cavaghan, K. I. Rother, D. Donaldson, D. M. Harlan, J. Bluestone, and K. C. Herold Insulin Secretion in Type 1 Diabetes Diabetes, February 1, 2004; 53(2): 426 - 433. [Abstract] [Full Text]

				C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]

				P. Hanifi-Moghaddam, N. C. Schloot, S. Kappler, J. Seissler, and H. Kolb An Association of Autoantibody Status and Serum Cytokine Levels in Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1137 - 1142. [Abstract] [Full Text] [PDF]

				M. R. Christie, J. Molvig, C. J. Hawkes, B. Carstensen, T. Mandrup-Poulsen, and the Canadian-European Randomised Control Trial Gro IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin Diabetes Care, July 1, 2002; 25(7): 1192 - 1197. [Abstract] [Full Text] [PDF]

				H. Borg, A. Gottsater, P. Fernlund, and G. Sundkvist A 12-Year Prospective Study of the Relationship Between Islet Antibodies and {beta}-Cell Function At and After the Diagnosis in Patients With Adult-Onset Diabetes Diabetes, June 1, 2002; 51(6): 1754 - 1762. [Abstract] [Full Text] [PDF]

				J. Graham, W. A. Hagopian, I. Kockum, L. S. Li, C. B. Sanjeevi, R. M. Lowe, J. B. Schaefer, M. Zarghami, H. L. Day, M. Landin-Olsson, et al. Genetic Effects on Age-Dependent Onset and Islet Cell Autoantibody Markers in Type 1 Diabetes Diabetes, May 1, 2002; 51(5): 1346 - 1355. [Abstract] [Full Text] [PDF]

				Z. Li, L. Zhao, S. Sandler, and F. A. Karlsson Expression of Pancreatic Islet MHC Class I, Insulin, and ICA 512 Tyrosine Phosphatase in Low-dose Streptozotocin-induced Diabetes in Mice J. Histochem. Cytochem., June 1, 2000; 48(6): 761 - 768. [Abstract] [Full Text]